The absorption and bioavailability of drugs can be limited by their solubility, dissolution rate, permeability or instability. The poor solubility of new chemical entities (NCEs) is one of the most frequent and greatest challenges to formulation scientists in the development of oral solid dosage forms. Pipeline of pharmaceutical companies are full of examples of NCEs pharmacologically effective but that have not reached the commercial launch due to an insufficient bioavailability.
In this educational webinar Dr. Flavio Fabiani will discuss the factors effecting absorption and bio-availability, how the candidate properties from discovery effect the formulation development and how the formulation chemist can adopt particular bio-enhancement strategies to make compounds drugable.
Dr. Flavio Fabiani, Senior Manager, Formulation and Material Science Group, Pharmaceutical & Preclinical Development, Aptuit Center for Drug Discovery & Development, Verona – Italy
Flavio has a degree in Chemical and Pharmaceutical Technologies obtained in 1993 from the University of Milan after a 18 months-period of experimental thesis carried out at Carlo Erba – Farmitalia Laboratories, Department of Galenica.
Flavio started his career in 1993 as a Formulation Scientist at Pharmatec International, a Contract Research and Manufacturing Organization. In 1997 Flavio moved to Grünenthal (the Italian subsidiary), where he was Responsible for the Pharmaceutical Development Laboratory, focusing on the manufacturing process transfer at commercial scale. At the end of 2000 Flavio was at Eurand International (currently Aptalispharma) as Formulation Group Manager, managing and leading the development of products for oral administration both as Contract Research and Manufacturing Organization and for Eurand/Aptalis proprietary products. His area of expertise also includes the development and improvement of technologies and drug delivery systems.
Who Should Attend?
- CMC Heads/Managers
- Project /Program leaders
- Lead Analysts
- Stability Managers and Specialists
- Regulatory Managers and Specialists
Aptuit LLC provides the most complete set of integrated early discovery to mid-phase drug development services in the Pharmaceutical industry including Drug Design & Discovery, API Development and Manufacture, Solid State Chemistry, CMC, and Preclinical and IND enabling GLP/GMP programs. Fully integrated drug discovery and development services are available from a single site at The Aptuit Center for Drug Discovery & Development in Verona, Italy. The company maintains resources around the world, with facilities in the US, UK and Italy. Aptuit LLC is partnered with Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors.
For more information about Aptuit, visit www.aptuit.com.